Negative in Ames, in vitro chromosome aberration and mouse bone marrow micronucleus assays
“Tucatinib did not induce mutations in the bacterial reverse mutation (Ames) assay and was not clastogenic in the in vitro chromosome aberration test or the in vivo mouse bone marrow micronucleus assay at doses up to the high dose of 2000 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Carcinogenicity
Not conducted (advanced cancer indication)
“No carcinogenicity studies were conducted or warranted to support this NDA, as the proposed indication was for advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Reproductive & developmental
Rat and rabbit EFD: teratogenic in rabbits, embryo-fetal toxicity in rats
“Tucatinib administered to pregnant dams caused teratogenicity in rabbits and embryo-fetal toxicity in rats.”
✓ VerifiedFDA multi-discipline review, p. 63Source ↗
Safety pharmacology
No adverse ECG, respiratory or neurobehavioral effects in safety pharmacology studies
“Tucatinib had no adverse effect on ECG, respiration, or neurological behavior in safety pharmacology studies.”
✓ VerifiedFDA multi-discipline review, p. 35Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative